Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Exelixis
National Institutes of Health Clinical Center (CC)
Day One Biopharmaceuticals, Inc.
Dartmouth-Hitchcock Medical Center
Day One Biopharmaceuticals, Inc.
Alaunos Therapeutics
University of Oklahoma
Dawonmedax Co., Ltd.
Ann & Robert H Lurie Children's Hospital of Chicago
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Celgene
University of California, San Francisco
University of Nebraska
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OncoSynergy, Inc.
Vanquish Oncology, Inc.
Rush University Medical Center
CENTOGENE GmbH Rostock
Karyopharm Therapeutics Inc
Rush University Medical Center
University of California, San Francisco
Indiana University
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
Pediatric Brain Tumor Consortium
Meyer Children's Hospital IRCCS
Massachusetts General Hospital
Tocagen Inc.
Northwestern University
Tocagen Inc.
Tocagen Inc.
Pfizer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
Medical University of South Carolina
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dr. Negrin University Hospital
Pediatric Brain Tumor Consortium
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Burzynski Research Institute
Burzynski Research Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota